Celebrity plastic surgery is everywhere right now, and the Kris Jenner and Denise Richards facelift stories have quietly touched off a real debate inside the plastic surgery world. In this episode of Beauty and the Beasts, Dr. Sam Jejurikar of Dallas and Dr. Salvatore Pacella of San Diego go past the headlines and talk through what is actually going on.

Two board-certified plastic surgeons explain why a third facelift at 70 is a completely different operation than a first facelift in your 50s, why the safest technique is often the smartest choice on a revision, and why almost everyone looks phenomenal at three months postop, a phenomenon one surgeon calls the siren of swelling. They get candid about how GLP-1 weight loss medications can quietly undo facelift and fat transfer results, the realistic healing timeline every patient should expect, how age and skin elasticity change the outcome, those six-figure price tags, and the uncomfortable trend of surgeons piling on one another online.

If you have ever wondered what a facelift really looks like as it ages, or how much of what you see on social media is filtered, swollen, or simply too good to be true, this is the honest conversation you have been looking for.

In this episode:
The two very different stories behind Kris Jenner and Denise Richards. Why filtered photos and early swelling make results look better than they will hold. The real timeline of recovery from three weeks to six months. First facelift versus third facelift and the risk to the facial nerve. Why GLP-1 medications matter more than most patients realize. What you are actually paying for when a facelift costs more than a car.

Beauty and the Beasts is hosted by Dr. Sam Jejurikar and Dr. Salvatore Pacella, two board-certified plastic surgeons sharing honest, behind-the-scenes conversations about aesthetic surgery, the industry, and the stories making headlines.

This episode is for educational and informational purposes only and is not medical advice. It does not create a doctor-patient relationship. Always consult a qualified, board-certified physician about your individual situation.

One in eight Americans is now on a GLP-1 medication like Ozempic, Wegovy, or Zepbound. The weight loss can be life-changing, but there is a side of this story that rarely gets talked about openly: what these medications are doing to your face, your skin, your muscle mass, your bone density, and your body contour.

In this episode, board-certified plastic surgeons Dr. Sam Jejurikar (Dallas, TX) and Dr. Sal Pacella (San Diego, CA) bring a combined four decades of surgical experience to one of the most pressing topics reshaping their practices today.

They break down the predictable patterns of facial volume loss they are seeing, including hollowing of the cheeks, temporal wasting, dark circles from mid-face descent, and loss of skin elasticity that goes beyond what you would expect from weight loss alone. They discuss why fat grafting results in GLP-1 patients may not be as durable as expected, and why GLP-1 receptors expressed on fat cells themselves may be to blame.

The episode features a lively disagreement on Sculptra: Dr. Pacella is firmly in the skeptic camp, calling it a reverse ATM machine, while Dr. Jejurikar makes the case that conservative, layered treatments delivered every six to eight weeks can serve as an effective volumizing foundation for the right patient. They also explore the promise and limitations of AlloClae cadaveric fat grafting, currently FDA approved for the breast and body but generating serious interest for facial applications.

The conversation then shifts to the body, covering the underappreciated impact of GLP-1s on muscle mass and bone density, why resistance training is now a clinical conversation happening in plastic surgery offices, and why brachioplasty and thigh lift volumes have increased fivefold in recent years. They also tackle Ozempic butt directly, explaining the combined role of fat loss, muscle atrophy, and pelvic structural changes, and why excisional lifting procedures are increasingly replacing the Brazilian Butt Lift for this growing patient population.

GLP-1 medications are not going anywhere. Newer agents, oral formulations, and triple-mechanism drugs like Retatrutide are already in the pipeline. For patients and surgeons alike, understanding the downstream effects is no longer optional.

Dr. Sam Jejurikar is a board-certified plastic surgeon and President of Dallas Plastic Surgery Institute. Dr. Sal Pacella is a board-certified plastic surgeon in private practice in San Diego, California. Together they host Beauty and the Beasts, a podcast dedicated to honest, unfiltered conversations about plastic surgery, aesthetics, and the science behind looking and feeling your best.

Follow Dr. Jejurikar on Instagram: @samjejurikar Follow Dr. Pacella on Instagram: @sandiegoplasticsurgeon

In this episode, Dr. Jejurikar and Dr. Pacella tackle one of the most underappreciated operations in cosmetic plastic surgery: the brow lift. Most patients never come in asking for one. They come in saying they look tired, they want something done about their eyes, and the brow is the hidden culprit. The guys break down why the high, pulled look of the 1990s coronal brow lift is outdated, why endoscopic brow lifts tend to disappoint over time, and why the subcutaneous sliding brow lift has become their preferred approach. They also get into the role of fat grafting in brow rejuvenation, the hemostatic net technique, and how Botox fits into the picture long-term. For male patients, the conversation shifts to brow stabilization rather than elevation, including the direct brow lift and the scarless trans-palpebral approach. If you've ever wondered why your upper eyelid surgery didn't give you the result you hoped for, this episode might explain why.